With regard to stopping therapy in the absence of AKI, there was agreement that treatment should be continued with levels of myoglobin between 5 and 10,000 ng/ml though at levels below 1000 ng/ml treatment should be stopped. The gene discussed is MB; the disease is acute kidney injury.